Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q1 2013 Earnings Presentation
18 slides from Chugai Pharmaceutical's earnings presentation, Apr 25, 2013
Slide 1: FY2013 1Q Consolidated Financial Overview (IFRS based)
Aiming to become “Top Pharmaceutical Company” FY2013 1Q Consolidated C lid t d Financial Fi i l Overview O i (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. E Executive ti Vice Vi P President id t CFO Yoshio Itaya April 25, 2013
Slide 2: Forward-Looking Statements
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview F Forward-Looking d L ki St Statements t t This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co.
Slide 3: Summary
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview Summary Revenues: 90 4 billion JPY (+0 90.4 (+0.1% 1% YoY) • Domestic sales excl. TAM: continued strong growth in oncology and new products more than offset the impact
Slide 4: IFRS and Core Results
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview IFRS and Core Results Non-Core items IFRS results Non-core Non core items Core results 1 IIntangible/Business 1. t ibl /B i 2013 Intangible assets 2013 combinations Bill
Slide 5: Financial Overview Jan - Mar, Year on Year (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan - Mar 2012 2013 (Billion JPY) ((Billion JPY)) Jan - Mar Jan - Mar Growth vs. Rev*. vs. Rev*. Royalties and other operating Rev
Slide 6: Sales (excl. Tamiflu) Jan - Mar, Year on Year
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview Year on Year Sales (excl (excl. Tamiflu) Jan - Mar (Billion JPY) Sales excl. excl Tamiflu 78.7 (-0.3, -0.4%) Overseas -1.7 Actemra A t Avastin A ti 79.0 (overseas) (15.8
Slide 7: Tamiflu Sales Performance
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales (Billion JPY) FY2009 12 FY2009.12 FY2010 12 FY2010.12 FY2011 12 FY2011.12 FY2012 12 FY2012.12 FY2013 12 FY2013.12 Cases per S
Slide 8: Operating Profit Jan - Mar, Year on Year (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan - Mar 2012 2013 (Billion JPY) (Billion JPY) Growth Jan - Mar Jan - Mar Revenues 90.3 90.4 +0.1 Cost of sales -39.4 -40.6 -1.2 Gr
Slide 9: Financial Overview Jan - Mar, vs. Forecast (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview vs. Forecast (Core) Financial Overview Jan - Mar Actual Forecast on Jan 30 2012 (Billion JPY) 2013 2013 Progress Progress* Jan - Mar Jan - Dec Revenues 90.4 416.0 21.7%
Slide 10: Domestic Sales (excl. Tamiflu) Jan - Mar, vs. Forecast
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview vs. Forecast Domestic Sales (excl. (excl Tamiflu) Jan - Mar Actual Forecast on Jan 30 2012 (Billion JPY) 2013 2013 Progress Progress* Jan - Mar Jan - Dec Domestic sales
Slide 11: Impact from Foreign Exchange, vs. Forecast (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 1Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange FX rate to the JPY 1CHF 1EUR Assumption Jan – Dec 95.00 115.00 (as of Jan. 30) Actual Jan – Mar avg. 99.19 121.80 FX imp
Slide 12: Overview of Development Pipeline
Aiming to become “Top Pharmaceutical Company” Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Project Planning & Coordination Dept. Hisanori Takanashi April 25, 2013
Slide 13: Development Status - Oncology
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status t - Oncology O l In- licensed RG597 / HerceptinⓇ: Expected Indication: Weekly Dosage with Chemo-Therapy for HER2 Positive Adjuvant Breast Cancer Filed
Slide 14: Development Status - Autoimmune
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status t - Autoimmune A t i In- house MRA / ActemraⓇ (sc): Indication: Rheumatoid Arthritis Approved in March 2013 13
Slide 15: Actemra Subcutaneous Formulation
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Actemra A t ® Subcutaneous S b t F Formulation l ti Actemra® 162 mg g Auto-Injector j for SC Injection j Date of Approval: March 25, 2013 Indications: Rheumatoid arthritis that
Slide 16: RG7414 (parsatuzumab) - Augmenting Anti-VEGF Therapy
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline RG7414（parsatuzumab） - Augmenting Anti-VEGF Therapy Increased & Tumor Growth Anti-Tumor Anti Tumor Activity Prolonged Anti-Tumor Anti-Angiogenic Sensitize Tumor Activity & Anti-V
Slide 17: RG7414 (parsatuzumab) - Mode of Action
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline RG7414（ RG7414（parsatuzumab） t b） - Mode M d off Action A ti EGFL7 （E id l Growth （Epidermal G th Factor-like F t lik domain d i 7） • Tumor-enriched vascular extracellular matrix
Slide 18: Contacts: Corporate Communications Dept.
Contacts: Corporate Communications Dept. Corporate Communications Group Tel: +81 81 (0)3 (0)3-3273-0881 3273 0881 Fax: +81 81 (0)3 (0)3-3281-6607 3281 6607 e-mail: pr@chugai-pharm.co.jp Hitoshi Aikawa, Koichi Kawahara, Hiroshi Araki, Sachiyo Yoshimura Investor Relations Group p Tel: +81 (0)3-3273-05
Chugai Pharmaceutical — Q1 2013 Earnings Presentation on 6ix